A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease
- 1 October 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 29 (10), 839-861
- https://doi.org/10.2165/11588390-000000000-00000
Abstract
Given rising healthcare costs and a growing population of patients with chronic kidney disease (CKD), there is an urgent need to identify health interventions that provide good value for money. For this review, the English-language literature was searched for studies of interventions in CKD reporting an original incremental cost-utility (cost per QALY) or cost-effectiveness (cost per life-year) ratio. Published cost studies that did not report cost-effectiveness or cost-utility ratios were also reviewed. League tables were then created for both cost-utility and cost-effectiveness ratios to assess interventions in patients with stage 1-4 CKD, waitlist and transplant patients and those with end-stage renal disease (ESRD). In addition, the percentage of cost-saving or dominant interventions (those that save money and improve health) was compared across these three disease categories. A total of 84 studies were included, contributing 72 cost-utility ratios, 20 cost-effectiveness ratios and 42 other cost measures. Many of the interventions were dominant over the comparator, indicating better health outcomes and lower costs. For the three disease categories, the greatest number of dominant or cost-saving interventions was reported for stage 1-4 CKD patients, followed by waitlist and transplant recipients and those with ESRD (91%, 87% and 55% of studies reporting a dominant or cost-saving intervention, respectively). There is evidence of opportunities to lower costs in the treatment of patients with CKD, while either improving or maintaining the quality of care. In order to realize these cost savings, efforts will be required to promote and effectively implement changes in treatment practices.Keywords
This publication has 119 references indexed in Scilit:
- Costing and Perspective in Published Cost-Effectiveness AnalysisMedical Care, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Cost-Effectiveness of Frequent In-Center HemodialysisJournal of the American Society of Nephrology, 2008
- Management and Prevention of Diabetic Foot Ulcers and InfectionsPharmacoEconomics, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysisBMC Nephrology, 2007
- The exclusion of patients with chronic kidney disease from clinical trials in coronary artery diseaseKidney International, 2006
- A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United StatesKidney International, 2004
- The Cost Effectiveness of Tacrolimus versus Microemulsified CyclosporinPharmacoEconomics, 2003
- Antihypertensive Treatment with and without Benazepril in Patients with Chronic Renal InsufficiencyPharmacoEconomics, 2002